Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00082786" target="_blank" >RIV/00216224:14110/15:00082786 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61988987:17110/15:A1601FXH RIV/00216208:11110/15:10296542 RIV/65269705:_____/15:00063093

Výsledek na webu

<a href="http://dx.doi.org/10.5507/bp.2015.014" target="_blank" >http://dx.doi.org/10.5507/bp.2015.014</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5507/bp.2015.014" target="_blank" >10.5507/bp.2015.014</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data

Popis výsledku v původním jazyce

Background. Multiple myeloma (MM) is characterized by malignant proliferation of plasma cells (PC) which accumulate in the bone marrow (BM). The advent of new drugs has changed the course of the disease from incurable to treatable, but most patients eventually relapse. One group of MM patients (10-15%) is considered high-risk because they relapse within 24 months. Recently, extramedullary relapse of MM (EM) has been observed more frequently. Due to its aggressivity and shorter survival, EM is also considered high-risk. Aims. The goal of this study was to determine if the so-called high-risk genes published by the University of Arkansas group (UAMS) are even more deregulated in EM patients than in high-risk MM patients and if these patients may be considered high-risk. Methods. Nine samples of bone marrow plasma cells from MM patients as well as 9 tumors and 9 bone marrow plasma cells from EM patients were used.

Název v anglickém jazyce

Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data

Popis výsledku anglicky

Background. Multiple myeloma (MM) is characterized by malignant proliferation of plasma cells (PC) which accumulate in the bone marrow (BM). The advent of new drugs has changed the course of the disease from incurable to treatable, but most patients eventually relapse. One group of MM patients (10-15%) is considered high-risk because they relapse within 24 months. Recently, extramedullary relapse of MM (EM) has been observed more frequently. Due to its aggressivity and shorter survival, EM is also considered high-risk. Aims. The goal of this study was to determine if the so-called high-risk genes published by the University of Arkansas group (UAMS) are even more deregulated in EM patients than in high-risk MM patients and if these patients may be considered high-risk. Methods. Nine samples of bone marrow plasma cells from MM patients as well as 9 tumors and 9 bone marrow plasma cells from EM patients were used.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biomedical Papers of the Faculty of Medicine of Palacký University, Olomouc, Czech Republic

ISSN

1213-8118

e-ISSN

—

Svazek periodika

159

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

6

Strana od-do

288-293

Kód UT WoS článku

000359128900020

EID výsledku v databázi Scopus

—